US Phlow Model And Drug Nationalism: Do Indian Firms Need To Be Watchful?

The new US public benefit pharma manufacturing firm Phlow has received significant federal funding in a bid to improve domestic supply security. Scrip speaks to prominent executives in India's industry over whether this model, if widely replicated, could put at risk the clout and market access plans of the Indian generic industry, a major supplier to the US market. 

Dollar sign made with drug pills
Does US Phlow approach signal changing market dynamics? • Source: Shutterstock

US federal backing for local start-up Phlow Corp. is generally seen as part of COVID-19-related "medicines nationalism" playing out as the US seeks to lower dependency on foreign nations to support its drug supply chain.

The collaborative effort, touted as a "defining moment and inflection point" for safeguarding the country from future public health threats, intends to bolster medicines security and provide a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip